Dendreon Submits Rolling BLA For Provenge Prostate Cancer Vaccine
This article was originally published in The Pink Sheet Daily
Executive Summary
Company says it is the first to submit a therapeutic cancer vaccine application to FDA.
You may also be interested in...
Dendreon's Provenge Therapeutic Cancer Vaccine Has A May 15 PDUFA Date
The prostate cancer immunotherapeutic is the first therapeutic cancer vaccine accepted for review by FDA.
Dendreon's Provenge Therapeutic Cancer Vaccine Has A May 15 PDUFA Date
The prostate cancer immunotherapeutic is the first therapeutic cancer vaccine accepted for review by FDA.
Introgen Anticipates Completion Of Advexin Rolling BLA Submission In 2007
Biologic may have synergistic effects with ImClone’s Erbitux and Genentech’s Avastin, firm tells “The Pink Sheet” DAILY.